Higher than when? Up until today, we have been led to believe by Teva that approval was due by the end of this month, but of course we were told earlier that approval would likely come by then end of last year, and before that...
As Dew has pointed out, Teva does not even say in today's PR that they expect approval. As Dew and others have pointed out, a Minor Deficiency letter does not mean that the information is easy to provide or that a drug is any closer to approval. Teva does not even say in their PR that they are confident that they can respond to the "short list of questions" to the satisfaction of the FDA.
Given Teva's track record of misleading PR regarding their generic Lovenox ANDA, why should anyone read today's PR as being anything different?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.